A291650 Stock Overview
Aptamer Sciences, Inc., a bio venture company, focuses on the Aptamer technology platform for the development of therapeutic and diagnostic platforms. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Aptamer Sciences Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,950.00 |
| 52 Week High | ₩4,190.00 |
| 52 Week Low | ₩1,763.00 |
| Beta | 0.38 |
| 11 Month Change | -22.77% |
| 3 Month Change | -9.51% |
| 1 Year Change | -44.44% |
| 33 Year Change | -78.27% |
| 5 Year Change | n/a |
| Change since IPO | -85.95% |
Recent News & Updates
Health Check: How Prudently Does Aptamer Sciences (KOSDAQ:291650) Use Debt?
Jul 26
Is Aptamer Sciences (KOSDAQ:291650) A Risky Investment?
Mar 26Shareholder Returns
| A291650 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -2.5% | -8.1% | 2.9% |
| 1Y | -44.4% | 18.1% | -2.8% |
Return vs Industry: A291650 underperformed the KR Biotechs industry which returned 18.1% over the past year.
Return vs Market: A291650 underperformed the KR Market which returned -2.8% over the past year.
Price Volatility
| A291650 volatility | |
|---|---|
| A291650 Average Weekly Movement | 22.8% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A291650's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A291650's weekly volatility has increased from 14% to 23% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | n/a | Dongil Han | www.aptsci.com |
Aptamer Sciences, Inc., a bio venture company, focuses on the Aptamer technology platform for the development of therapeutic and diagnostic platforms. The company’s aptamer platforms include aptamer discovery, optimization, and the development of therapeutics and diagnostics. It offers AlloMAp and BiFAp platform programs for therapeutics; and diagnosis kits for lung and pancreatic cancer, as well as in-vitro diagnostic kits for the early diagnosis of lung cancer.
Aptamer Sciences Inc Fundamentals Summary
| A291650 fundamental statistics | |
|---|---|
| Market cap | ₩33.11b |
| Earnings (TTM) | -₩13.48b |
| Revenue (TTM) | ₩216.07m |
153.2x
P/S Ratio-2.5x
P/E RatioIs A291650 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A291650 income statement (TTM) | |
|---|---|
| Revenue | ₩216.07m |
| Cost of Revenue | ₩45.87m |
| Gross Profit | ₩170.20m |
| Other Expenses | ₩13.65b |
| Earnings | -₩13.48b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -793.70 |
| Gross Margin | 78.77% |
| Net Profit Margin | -6,237.59% |
| Debt/Equity Ratio | 66.3% |
How did A291650 perform over the long term?
See historical performance and comparison